$PEPG added at 4.5, averaging down to 4.95. Will add more at 4. Surely, the lower, the better.
2
11
2,597
$NVDA CEO Jansen Huang got ousted for his affair with a lady, wiping out hundreds of billions of market value. What could be sadder than this for a successful American company? It proved traditional Chinese wisdom again: For a man, nothing is more risky than a lady.
$PEPG will good data (~50% splicing, acceptable safety) from high dose cohort (12.5mg/kg) in 1H27 and 1 year follow-up from lower dose qualify NDA for accelerated approval? if yes, this stock is way too cheap under $1B valuation right now.
$PEPG initiated a long pos at 5.5. 46% splicing correction for DM1 is so good. It's pII trial at dose of 10mg/kg. high dose 12.5mg/kg data 1H27. From pI single dose study, 15mg/kg achieved 53.7% mean splicing. So I expect 12.5mg/kg dose should give around 50% splicing. Strong Buy
$INO $70m offering at 1.05 before discount, ripping off shareholders again, esp. naive new retail investors who bought it on FDA approval. i only see it will bleed faster and dilute more before seeing any revenue. this 70m will be gone even the confirmatory trial starts.
$CNTB does it and its Chinese partner Simere Pharm have a better version of Dupixent? Simere submitted NDA for atopic dermatitis in China (approval by April 2027). Dupixent sales total 5.7B euro 3Q26: bloomberg.com/news/articles/…
1
2
1,568
Why $CNTB stock price stays under 1? Please share some of your insights please.
1
705
Nick zheng retweeted
Replying to @jy201506
$IOVA to reload it at single digit sounds like a dream just a few days ago :-) Is the company worth $4B? I bet.
11
1,484
$IOVA back to single digit (down 36% to 9.4). Waiting to reload it. (I sold too earlier before it jumped on revenue bumping up). Good big view: The only TIL therapy with increasing revenue (next year should be over 500M). Bad view: expanding from melanoma to NSCLC may take longer




